Melanoma vaccine promising for intermediate outcomes

May 1, 2001

Venice, Italy - A vaccine made from two lines of lysed human melanoma cells combined with an immunologic adjuvant appears to reduce the rates of recurrence and death in some patients with Stage IIa melanoma.